Status:

RECRUITING

Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation

Lead Sponsor:

Ottawa Heart Institute Research Corporation

Collaborating Sponsors:

Heart and Stroke Foundation of Canada

Conditions:

Atrial Fibrillation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A multicentre, parallel group, two arm, single-blinded randomized clinical trial, assessing the efficacy of a patient-tailored catheter ablation (CA) strategy guided by atrial scar mapping in addition...

Detailed Description

The optimal CA strategy for persistent AF remains unknown. Current data highlight the need for a better understanding of the substrate and mechanisms of arrhythmia maintenance in this population. Atri...

Eligibility Criteria

Inclusion

  • Age ≥18 years ;
  • Subjects with symptomatic persistent AF AND clinically indicated catheter ablation for AF
  • At least one episode of AF that is sustained beyond 3 months in duration ; documented on 12-lead ECG, Holter monitor, loop monitor or trans-telephonic monitor (TTM) within 36 months of enrollment in the study;
  • Modified DR-FLASH score \>=4
  • 4\. Subjects must be able to provide informed consent.

Exclusion

  • History of previous catheter ablation for AF or left atrial flutter;
  • History of previous surgical ablation for AF;
  • Known intracardiac thrombus;
  • Contraindication to systemic oral anticoagulation therapy;
  • Reversible causes of AF;
  • Hypertrophic cardiomyopathy;
  • Severe valvular disease (mitral/aortic stenosis or regurgitation);
  • Subjects that are pregnant or breastfeeding;
  • Comorbid condition with life expectancy \< 1 year

Key Trial Info

Start Date :

August 24 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2024

Estimated Enrollment :

502 Patients enrolled

Trial Details

Trial ID

NCT03347227

Start Date

August 24 2018

End Date

December 1 2024

Last Update

May 8 2024

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Libin Cardiovascular Institute

Calgary, Alberta, Canada

2

Vancouver General Hospital

Vancouver, British Columbia, Canada

3

QEII Health Sciences Centre, Nova Scotia Health Authority

Halifax, Nova Scotia, Canada, B3H 1V7

4

Hamilton General Hospital

Hamilton, Ontario, Canada